Every medicine for any disease has side effects, and theres always a risk-to-benefit ratio to consider, Jastreboff added
history of or active ischemic, hemorrhagic or anatomical neurovascular disease, including transient ischemic attack, cerebrovascular accident, arteriovenous malformation or brain aneurysm, peripheral vascular disease such as deep vein thrombosis/pulmonary embolism, chronic venous insufficiency, claudication or lymphedema
Benefits have been demonstrated in those with mild cognitive impairment as well
Exendin-4 and liraglutide reduced the expression of genes involved in cholesterol synthesis ( ACAT1 , SREBP-2 , HMGCR , and SQLE ), bile acid synthesis ( LXR and CYP7A1 ), and the PCSK9 gene, while increasing the expression of genes associated with the RCT pathway ( ABCA1 and SR-B1 ) and LDL-C uptake ( LDLR )
Clinical improvement was also observed in oxidative stress markers, with improvements in methionine levels (p=0.05), homocysteine levels (SAH, p=0.007) and the ratio of S-adenosylmethionine (SAMe) to SAH (p=0.007), indicating improvement with methylation at the cellular level and a decrease in oxidative stress in the body 2
